Earnings Summary

Novartis Ag’s revenue jumped 8.93% since last year same period to $13172Mn in the Q3 2024. On a quarterly growth basis, Novartis Ag has generated 5.27% jump in its revenue since last 3-months.

Novartis Ag’s net profit jumped 81.09% since last year same period to $3189Mn in the Q3 2024. On a quarterly growth basis, Novartis Ag has generated -1.76% fall in its net profits since last 3-months.

Novartis Ag’s net profit margin jumped 66.24% since last year same period to 24.21% in the Q3 2024. On a quarterly growth basis, Novartis Ag has generated -6.68% fall in its net profit margins since last 3-months.

Novartis Ag’s price-to-earnings ratio after this Q3 2024 earnings stands at 17.99.

Novartis Ag’s earning per share (EPS) estimates for the current quarter stand at 1.96 - a 3.7% jump from last quarter’s estimates.

Novartis Ag’s earning per share (EPS) estimates for the current year stand at 1.96.

Novartis Ag’s earning per share (EPS) jumped 12.57% since last year same period to 2.06 in the Q3 2024. This indicates that the Novartis Ag has generated 12.57% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Novartis Ag’s return on assets (ROA) stands at 0.11.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Novartis Ag’s return on equity (ROE) stands at 0.29.